open access

Vol 55, No 2 (2017)
Original paper
Submitted: 2016-11-27
Accepted: 2017-05-11
Published online: 2017-05-18
Get Citation

Inhibition of EGFR nuclear shuttling decreases irradiation resistance in HeLa cells

Hong Wei1, Zijie Zhu1, Longtao Lu1
DOI: 10.5603/FHC.a2017.0007
·
Pubmed: 28518211
·
Folia Histochem Cytobiol 2017;55(2):43-51.
Affiliations
  1. Central Laboratory of Weifang Hospital of Traditional Chinese Medicine, Weifang, Shangdong Province, China

open access

Vol 55, No 2 (2017)
ORIGINAL PAPERS
Submitted: 2016-11-27
Accepted: 2017-05-11
Published online: 2017-05-18

Abstract

Introduction. Cervical cancer is a leading cause of mortality in women worldwide. The resistance to irradiation at the advanced stage is the main reason for the poor prognosis and high mortality. This work aims to elucidate the molecular mechanism underlying the radio-resistance.

Material and methods. In this study, we determined the pEGFR-T654 and pDNA-PK-T2609 expression level changes in irradiated HeLa cells treated with T654 peptide, a nuclear localization signal (NLS) inhibitor, to inhibit EGFR nuclear transport. Cell viability, cell cycle and migratory capacity were analyzed. Xenograft animal model was used to evaluate the effect of EGFR nuclear transport inhibition on the tumor growth in vivo.

Results. The enhanced translocation of nuclear EGFR in the irradiated HeLa cells correlated with the increasing level of pEGFR-T654 and pDNA-PK-T2609. Inhibition of EGFR nuclear translocation by NLS peptide inhibitor attenuated DNA damage repair in the irradiated HeLa cells, decreased cell viability and promoted cell death through arrest at G0 phase. NLS peptide inhibitor impaired the migratory capacity of irradiated HeLa cells, and negatively affected tumorigenesis in xenograft mice.

Conclusions. This work puts forward a potential molecular mechanism of the irradiation resistance in cervical cancer cells, providing a promising direction towards an efficient therapy of cervical cancer.

Abstract

Introduction. Cervical cancer is a leading cause of mortality in women worldwide. The resistance to irradiation at the advanced stage is the main reason for the poor prognosis and high mortality. This work aims to elucidate the molecular mechanism underlying the radio-resistance.

Material and methods. In this study, we determined the pEGFR-T654 and pDNA-PK-T2609 expression level changes in irradiated HeLa cells treated with T654 peptide, a nuclear localization signal (NLS) inhibitor, to inhibit EGFR nuclear transport. Cell viability, cell cycle and migratory capacity were analyzed. Xenograft animal model was used to evaluate the effect of EGFR nuclear transport inhibition on the tumor growth in vivo.

Results. The enhanced translocation of nuclear EGFR in the irradiated HeLa cells correlated with the increasing level of pEGFR-T654 and pDNA-PK-T2609. Inhibition of EGFR nuclear translocation by NLS peptide inhibitor attenuated DNA damage repair in the irradiated HeLa cells, decreased cell viability and promoted cell death through arrest at G0 phase. NLS peptide inhibitor impaired the migratory capacity of irradiated HeLa cells, and negatively affected tumorigenesis in xenograft mice.

Conclusions. This work puts forward a potential molecular mechanism of the irradiation resistance in cervical cancer cells, providing a promising direction towards an efficient therapy of cervical cancer.

Get Citation

Keywords

EGFR; HeLa; nuclear translocation; pEGFR-T654; pDNA-PK-T2609; NLS peptide inhibitor; cell migration; xenograft

About this article
Title

Inhibition of EGFR nuclear shuttling decreases irradiation resistance in HeLa cells

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 55, No 2 (2017)

Article type

Original paper

Pages

43-51

Published online

2017-05-18

DOI

10.5603/FHC.a2017.0007

Pubmed

28518211

Bibliographic record

Folia Histochem Cytobiol 2017;55(2):43-51.

Keywords

EGFR
HeLa
nuclear translocation
pEGFR-T654
pDNA-PK-T2609
NLS peptide inhibitor
cell migration
xenograft

Authors

Hong Wei
Zijie Zhu
Longtao Lu

References (29)
  1. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005; 353(20): 2101–2104.
  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6): 1374–1403.
  3. Zhao Y, Shen L, Chen Xi, et al. High expression of PKM2 as a poor prognosis indicator is associated with radiation resistance in cervical cancer. Histol Histopathol. 2015; 30(11): 1313–1320.
  4. Kim MK, Kim TJ, Sung COk, et al. High expression of mTOR is associated with radiation resistance in cervical cancer. J Gynecol Oncol. 2010; 21(3): 181–185.
  5. Xia S, Zhao Y, Yu S, et al. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm. 2010; 25(3): 317–323.
  6. Cho S, Cinghu S, Yu JR, et al. Helicase-like transcription factor confers radiation resistance in cervical cancer through enhancing the DNA damage repair capacity. J Cancer Res Clin Oncol. 2011; 137(4): 629–637.
  7. Kim TJ, Lee JW, Song SY, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer. 2006; 94(11): 1678–1682.
  8. Chung YM, Kim BG, Park CS, et al. Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. Int J Cancer. 2005; 117(2): 194–201.
  9. Qureshi R, Arora H, Biswas S, et al. Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients. Tumour Biol. 2016; 37(7): 9089–9098.
  10. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2): 127–137.
  11. Singh D, Attri BK, Gill RK, et al. Review on EGFR Inhibitors: Critical Updates. Mini Rev Med Chem. 2016; 16(14): 1134–1166.
  12. Li C, Iida M, Dunn EF, et al. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009; 28(43): 3801–3813.
  13. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 2011; 71(3): 1103–1114.
  14. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol. 2005; 76(2): 157–161.
  15. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys. 2004; 58(3): 903–913.
  16. Dittmann K, Mayer C, Fehrenbacher B, et al. Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett. 2010; 584(18): 3878–3884.
  17. Zhao M, Ma Q, Xu J, et al. Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models. Oncol Lett. 2015; 10(2): 768–772.
  18. Biscardi JS, Maa MC, Tice DA, et al. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 1999; 274(12): 8335–8343.
  19. Iida M, Brand TM, Campbell DA, et al. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 2013; 32(6): 759–767.
  20. Li Z, Hosoi Y, Cai K, et al. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation. Biochem Biophys Res Commun. 2006; 341(2): 363–368.
  21. Santiago A, Eicheler W, Bussink J, et al. Effect of cetuximab and fractionated irradiation on tumour micro-environment. Radiother Oncol. 2010; 97(2): 322–329.
  22. Dittmann K, Mayer C, Wanner G, et al. The radioprotector O-phospho-tyrosine stimulates DNA-repair via epidermal growth factor receptor- and DNA-dependent kinase phosphorylation. Radiother Oncol. 2007; 84(3): 328–334.
  23. Wanner G, Mayer C, Kehlbach R, et al. Activation of protein kinase Cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol. 2008; 86(3): 383–390.
  24. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005; 280(35): 31182–31189.
  25. Dittmann K, Mayer C, Rodemann HP, et al. EGFR cooperates with glucose transporter SGLT1 to enable chromatin remodeling in response to ionizing radiation. Radiother Oncol. 2013; 107(2): 247–251.
  26. Jean C, Blanc A, Prade-Houdellier N, et al. Epidermal growth factor receptor/beta-catenin/T-cell factor 4/matrix metalloproteinase 1: a new pathway for regulating keratinocyte invasiveness after UVA irradiation. Cancer Res. 2009; 69(8): 3291–3299.
  27. Bozec A, Formento P, Lassalle S, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer. 2007; 97(1): 65–72.
  28. Rothkamm K, Krüger I, Thompson LH, et al. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003; 23(16): 5706–5715.
  29. Makita N, Ninomiya I, Tsukada T, et al. Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells. Oncol Rep. 2015; 34(3): 1185–1192.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl